Innocens is a biotech spin-off from the University of Antwerp building an AI-based Clinical Decision Support System for neonatal intensive care units. The software delivers 24/7 risk predictions to help caregivers detect early signs of infections, sepsis, and other complications in premature or critically ill newborns. With its technology, the company aims to improve clinical outcomes and reduce the workload of NICU staff. The recently secured capital will fund a new clinical validation study and enable Innocens to obtain CE regulatory certification, both prerequisites for broader market entry. Management will also use the money to strengthen the team’s competencies and accelerate the commercial rollout across Europe. Although no operating revenue or user metrics are disclosed, the company completed an initial financing round in 2023 and views the latest capital injection as a bridge to full commercialization.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025